drugset / Trial / NCT05768919
Study of Liposomal Curcumin in Combination With RT and TMZ in Patients With Newly Diagnosed High-Grade Gliomas
NaSequentialOpen-labelTreatment
Summary
The objective of this study is to assess the tolerability, safety, and efficacy of Liposomal Curcumin (LC) in combination with radiotherapy (RT) and Temozolomide (TMZ) in patients with newly diagnosed High-Grade Gliomas (HGG).
Timeline
- Start
- 2023-03-03
- Primary completion
- 2026-02
- Completion
- 2027-05
Publications
- Background Sordillo PP, Sordillo LA, Helson L. The Kynurenine Pathway: A Primary Resistance Mechanism in Patients with Glioblastoma. Anticancer Res. 2017 May;37(5):2159-2171. doi: 10.21873/anticanres.11551.
- Background Glioblastoma cell-induced immunosuppression causing chemoresistance. Chapter in: Glioblastoma Resistance to Chemotherapy: Molecular Mechanisms and Innovative Reversal Strategies. Elsevier/Academic Press. 2021
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Curcumin | Small molecule | 300 mg/m2 | Intravenous |
| Background | Dexamethasone | Small molecule | 4 mg | Intravenous |
| Background | Diphenhydramine | Unknown | 25 mg | Intravenous |
| Background | Treatment Period 1 | Unknown | 75 mg/m2 | Oral |
| Background | Treatment Period 1 | Unknown | 150 mg/m2 | Oral |
| Background | Treatment Period 1 | Unknown | 200 mg/m2 | Oral |